Author: Tom Wilemon
Drug modifies epigenome in aggressive brain tumors: study
Jan. 5, 2022—A folic acid-like drug changed a DNA process within brain tumors of glioblastoma patients, according to results from a phase 1 clinical trial.
Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate
Dec. 24, 2021—New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death.
Study sets framework for precision surveillance of colorectal cancer
Dec. 14, 2021—Vanderbilt research has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the cancer utilizing precision medicine.
Reid selected for clinical trial development program
Dec. 2, 2021—Vanderbilt's Sonya Reid, MD, MPH, has been selected to participate in the first cohort of the Bristol Myers Squibb Foundation Clinical Trial Diversity Career Development Program.
Team receives Association of Community Cancer Centers Innovator Award
Nov. 18, 2021—A team of Vanderbilt employees have received and award for implementing a streamlined follow-up protocol for patients who may not know they have cancer.
Chic Awearness gala to support ovarian cancer research set for Dec. 6
Nov. 18, 2021—Chic Awearness, a fashion show and fundraiser for ovarian cancer research, returns as an in-person event from 6:30 p.m. to 8:30 p.m. on Monday, Dec. 6.
Koerkenmeier named VICC associate nursing officer
Nov. 4, 2021— by Tom Wilemon Clint Koerkenmeier, MHS, RN, is the new associate nursing officer at Vanderbilt-Ingram Cancer Center (VICC) with the responsibility for supervising the ambulatory oncology nursing enterprise. He came to Vanderbilt from MD Anderson Cancer Center following the departure of his predecessor, Anna Rodriguez, MSN, MHA, RN, who is now chief nursing officer...
Reid receives NRG Oncology early-stage investigator award
Oct. 28, 2021—Vanderbilt's Sonya Reid, MD, MPH, is a recipient of an NRG Oncology Underserved Minority Scholars Award.
VICC’s Mayer departing to take new role with AstraZeneca
Oct. 28, 2021—Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca.
Study to evaluate how environment impacts cancer risk
Oct. 21, 2021—Vanderbilt-Ingram Cancer Center is leading an ambitious project to assess the impact of environmental exposures on cancer risk for people living in Southern states.
Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer
Oct. 14, 2021—Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.
Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription
Sep. 30, 2021—Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.
